XASX
1AD
Market cap1mUSD
Oct 09, Last price
0.00AUD
1D
-14.29%
1Q
-25.00%
Jan 2017
-98.17%
IPO
-98.85%
Name
Adalta Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
112.45%
Rev. gr., 5y
-29.28%
Revenues
0
-100.00%
Net income
-5m
L+4.03%
CFO
-4m
L+51.20%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other related fibrotic diseases. The company has forged strategic alliances, including a collaboration with GE Healthcare to identify i-bodies that bind to granzyme B, and a partnership with Carina Biotech Pty Ltd. focused on developing CAR-T cell products designed to target various solid tumor antigens. AdAlta Limited was founded in 2006 and is headquartered in Bundoora, Australia.
Key people
Paul MacLeman
Non-Executive Chairman of the Board · since 2022
Timothy Oldham
Chief Executive Officer, Managing Director, Executive Director · since 2022
Michael Foley
Chief Scientific Officer
Company Secretary · since 2017
Michelle Burke
Non-Executive Director · since 2024
David Fuller
Non-Executive Director · since 2020
Non-Executive Director · since 2024
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||